SAN DIEGO & SILVER SPRING, Md.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of United Therapeutics Corporation (NasdaqGS: UTHR) breached their fiduciary duties to shareholders. United Therapeutics, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide.
View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/united-therapeutics-corporation
United Therapeutics Reveals Details of Potential Settlement
On July 27, 2017, United Therapeutics disclosed that it set aside $210 million for a possible settlement related to an investigation by the U.S. Department of Justice involving the company's donations to nonprofit organizations that give patients financial assistance to pay their out-of-pocket drug expenses. The investigation concerns whether these financial contributions violate the Federal Anti-Kickback Statute and the Federal False Claims Act. United Therapeutics further revealed that it is prepared to enter into a corporate-integrity agreement with the federal government that may obligate the company to comply with certain business practices for a number of years.
United Therapeutics Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
